NCT04447768 - The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Obinutuzumab

"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"

DRUG

Venetoclax

"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All protocol activities), Harrison

11553

Memorial Sloan Kettering Nassau (All protocol activities), Uniondale

11725

Memorial Sloan Kettering Commack (All protocol activities), Commack

27514

University of North Carolina, Chapel Hill

94305-5408

Stanford University Medical Center (Data collection only), Stanford

07920

Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown